Protection is not always a good thing: The immune system’s impact on gene therapy

Freitas, Martiela Vaz de; Frâncio, Lariane; Haleva, Laura; Matte, Úrsula da Silveira

doi:10.1590/1678-4685-gmb-2022-0046

Cited by 7 publications

(4 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compounds known as immune modulators control the immunological response by either increasing immune activation or decreasing inflammation. [28] The potential of agents like interleukins, interferons, and toll-like receptor agonists to increase antiviral immunity in HIV-positive people is being studied. According to Clutton et al, [29] interleukin-10 enhances the production of CD8 + T cells.…”

Section: Methods Of Immunotherapy For Hiv Managementmentioning

confidence: 99%

See 1 more Smart Citation

Toward a cure – Advancing HIV/AIDs treatment modalities beyond antiretroviral therapy: A Review

Alum,

Uti,

Ugwu

et al. 2024

Medicine

View full text Add to dashboard Cite

Antiretroviral therapy, also known as antiretroviral therapy (ART), has been at the forefront of the ongoing battle against human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDs). ART is effective, but it has drawbacks such as side effects, medication resistance, and difficulty getting access to treatment, which highlights the urgent need for novel treatment approaches. This review explores the complex field of HIV/AIDS treatment, covering both established alternative treatment modalities and orthodox antiretroviral therapy. Numerous reliable databases were reviewed, including PubMed, Web of Science, Scopus, and Google Scholar. The results of a thorough literature search revealed numerous therapeutic options, including stem cell transplantation, immunotherapy, gene therapy, latency reversal agents, and pharmaceutical vaccinations. While gene therapy has promise for altering cellular resistance to infection and targeting HIV-positive cells, immunotherapy treatments seek to strengthen the immune system’s ability to combat HIV. Latency reversal agents offer a promising method of breaking the viral latency and making infected cells vulnerable to immune system destruction or antiretroviral drugs. Furthermore, there is potential for improving immune responses against HIV using medical vaccinations. This review stresses the vital significance of ongoing research and innovation in the hunt for a successful HIV/AIDS treatment through a thorough examination of recent developments and lingering challenges. The assessment notes that even though there has been tremendous progress in treating the illness, there is still more work to be done in addressing current barriers and investigating various treatment options in order to achieve the ultimate objective of putting an end to the HIV/AIDS pandemic.

show abstract

Section: Methods Of Immunotherapy For Hiv Managementmentioning

confidence: 99%

“…Gene therapy may eventually provide a workable cure for the virus. [28] 6.1.1. Cas9/CRISPR technology.…”

Section: Methods Of Immunotherapy For Hiv Managementmentioning

confidence: 99%

Toward a cure – Advancing HIV/AIDs treatment modalities beyond antiretroviral therapy: A Review

Alum,

Uti,

Ugwu

et al. 2024

Medicine

View full text Add to dashboard Cite

show abstract

“…To avoid unfavorable immune responses, immunosuppressive drugs are often co-administered, a strategy employed by clinical trials using CRISPR ( Gillmore et al, 2021 ), other gene therapy approaches ( Corti et al, 2017 ; Mendell et al, 2017 ; Russell et al, 2017 ; Freitas et al, 2022 ), or cellular therapies ( Ramzy et al, 2021 ; Shapiro et al, 2021 ). Corticosteroids are approved for use with two AAV-based gene therapy drugs in clinical use, Zolgensma ( Mendell et al, 2017 ) and Luxturna ( Russell et al, 2017 ).…”

Section: Considerations To Mitigate Immunogenicity For Clinical Trans...mentioning

confidence: 99%

Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation

Ewaisha

Anderson

2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

CRISPR offers new hope for many patients and promises to transform the way we think of future therapies. Ensuring safety of CRISPR therapeutics is a top priority for clinical translation and specific recommendations have been recently released by the FDA. Rapid progress in the preclinical and clinical development of CRISPR therapeutics leverages years of experience with gene therapy successes and failures. Adverse events due to immunogenicity have been a major setback that has impacted the field of gene therapy. As several in vivo CRISPR clinical trials make progress, the challenge of immunogenicity remains a significant roadblock to the clinical availability and utility of CRISPR therapeutics. In this review, we examine what is currently known about the immunogenicity of CRISPR therapeutics and discuss several considerations to mitigate immunogenicity for the design of safe and clinically translatable CRISPR therapeutics.

show abstract

“…The immune system's identification of these viral vectors as intruders might trigger a defensive reaction, potentially neutralizing the intended therapeutic impact and inducing inflammatory reactions [317]. Moreover, the expression of therapeutic genes or proteins could trigger inflammatory responses, culminating in tissue impairment or untoward reactions [318]. Assuring the prolonged safety of gene therapy constitutes a formidable task.…”

Section: Gene Therapymentioning

confidence: 99%

The Long and Winding Road to Cardiac Regeneration

Sacco,

Castaldo,

Di Meglio

et al. 2023

Applied Sciences

View full text Add to dashboard Cite

Cardiac regeneration is a critical endeavor in the treatment of heart diseases, aimed at repairing and enhancing the structure and function of damaged myocardium. This review offers a comprehensive overview of current advancements and strategies in cardiac regeneration, with a specific focus on regenerative medicine and tissue engineering-based approaches. Stem cell-based therapies, which involve the utilization of adult stem cells and pluripotent stem cells hold immense potential for replenishing lost cardiomyocytes and facilitating cardiac tissue repair and regeneration. Tissue engineering also plays a prominent role employing synthetic or natural biomaterials, engineering cardiac patches and grafts with suitable properties, and fabricating upscale bioreactors to create functional constructs for cardiac recovery. These constructs can be transplanted into the heart to provide mechanical support and facilitate tissue healing. Additionally, the production of organoids and chips that accurately replicate the structure and function of the whole organ is an area of extensive research. Despite significant progress, several challenges persist in the field of cardiac regeneration. These include enhancing cell survival and engraftment, achieving proper vascularization, and ensuring the long-term functionality of engineered constructs. Overcoming these obstacles and offering effective therapies to restore cardiac function could improve the quality of life for individuals with heart diseases.

show abstract

Protection is not always a good thing: The immune system’s impact on gene therapy

Cited by 7 publications

References 113 publications

Toward a cure – Advancing HIV/AIDs treatment modalities beyond antiretroviral therapy: A Review

Toward a cure – Advancing HIV/AIDs treatment modalities beyond antiretroviral therapy: A Review

Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation

The Long and Winding Road to Cardiac Regeneration

Contact Info

Product

Resources

About